Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
Preoperative treatment with elacestrant in early breast cancer demonstrated relevant biological and molecular responses and exhibited a manageable safety profile. These findings support further investigation of elacestrant in the early setting.
Authors
- María Vidal (ORCID: https://orcid.org/0000-0003-1992-5727)
- Christian Sisó (ORCID: https://orcid.org/0000-0002-7217-1541)
- Claudette Falato (ORCID: https://orcid.org/0000-0003-4055-4764)
- Meritxell Bellet (ORCID: https://orcid.org/0000-0001-8859-8307)
- Xavier González (ORCID: https://orcid.org/0000-0002-5797-7037)
- Milana A. Bergamino (ORCID: https://orcid.org/0000-0002-1091-2711)
- Isaac Cebrecos (ORCID: https://orcid.org/0000-0002-9333-3642)
- Miguel A. Luna (ORCID: https://orcid.org/0000-0002-9253-3677)
- J.M. Ferrero-Cafiero (ORCID: https://orcid.org/0000-0001-8796-8812)
- Alejandra Espinosa Guerrero (ORCID: https://orcid.org/0000-0002-7193-9563)
- Tomás Pascual (ORCID: https://orcid.org/0000-0001-8431-3183)
- Rodrigo Sánchez-Bayona (ORCID: https://orcid.org/0000-0002-5255-6620)
- Mireia Margelí Vila (ORCID: https://orcid.org/0000-0003-3594-4530)
- Patricia Galván (ORCID: https://orcid.org/0000-0002-8153-0307)
- Esther Sanfeliu (ORCID: https://orcid.org/0000-0002-7974-3346)
- Laia Paré (ORCID: https://orcid.org/0000-0002-4904-558X)
- Fernando Salvador (ORCID: https://orcid.org/0000-0002-5442-1754)
- Kepa Amillano (ORCID: https://orcid.org/0000-0002-4961-9328)
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- Tomás Cortadellas (ORCID: https://orcid.org/0000-0001-7225-7954)
Institutions
- Universitat Autònoma de Barcelona (ES)
- Institut Català d'Ornitologia (ES)
- Breast Cancer Research Foundation (US)
- Karolinska Institutet (SE)
- Research Institute Hospital 12 de Octubre (ES)
- Instituto Oncológico Dr. Rosell (ES)
- Hospital Universitario 12 De Octubre (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Institut Català d'Oncologia (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital General de Catalunya (ES)
- Institute for Research in Biomedicine (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Solti (ES)
- Badalona Serveis Assistencials (ES)
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- Oryzon Genomics (Spain) (ES)
- Hospital Universitari Sant Joan de Reus (ES)
- Spanish Ovarian Cancer Research Group (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2460
- Citations
- 6
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.62
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Eisai
- Daiichi Sankyo Europe